NCT03862677 Determining Prognostic Immune Markers in Patients With Ovarian Cancer
| NCT ID | NCT03862677 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Leiden University Medical Center |
| Condition | Epithelial Ovarian Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2020-08-15 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2020-08-15 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
Eligibility Criteria
Inclusion Criteria: * Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and/or immunotherapy. * Age ≥18 years. * WHO performance status 0-2. * Accessible for treatment and follow-up. * Written informed consent. Exclusion Criteria: * Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer. * Any known severe infection like HIV, hepatitis A, B and C. * Receiving immune suppressive treatment. * Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
Contact & Investigator
Judith R Kroep, MD PhD
PRINCIPAL INVESTIGATOR
Leiden University Medical Center
Frequently Asked Questions
Who can join the NCT03862677 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Epithelial Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03862677 currently recruiting?
Yes, NCT03862677 is actively recruiting participants. Contact the research team at j.r.kroep@lumc.nl for enrollment information.
Where is the NCT03862677 trial being conducted?
This trial is being conducted at Leiden, Netherlands.
Who is sponsoring the NCT03862677 clinical trial?
NCT03862677 is sponsored by Leiden University Medical Center. The principal investigator is Judith R Kroep, MD PhD at Leiden University Medical Center. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.